Bioz has raised $44.0M in total across 3 funding rounds.
Bioz's investors include BoxOne Ventures, Harmonix Fund, Pioneer Fund, Mathieu Guerville, Storm Ventures, Wildcat Ventures, Thomvest Ventures.
Bioz is an AI-driven search engine and evidence‑based recommendation platform that helps life‑science researchers discover, validate, and buy reagents, instruments, and experimental methods by mining the scientific literature with natural language processing and machine learning.[1][4]
High‑Level Overview
Bioz’s mission is to accelerate scientific research and drug discovery by putting publication‑backed experimental knowledge at researchers’ fingertips so they can make faster, more reproducible decisions in the lab.[2][1]
Its core product philosophy centers on evidence‑based product discovery: rank and recommend products based on real usage in peer‑reviewed papers (frequency, recency and journal impact), then surface those citations to researchers and suppliers.[4][1]
Key sectors served are academic life science research and biopharma R&D (researchers, lab managers, and scientific product suppliers), with commercial offerings to both end users (subscription search) and vendors (content syndication / site widgets). [3][1]
Impact on the startup and scientific ecosystem includes reducing time and cost of experimental selection, increasing transparency for suppliers through citation‑based validation, and helping accelerate translational research and drug discovery by improving experimental decision quality.[2][3]
Origin Story
Bioz was founded in 2013 by Stanford research scientist Dr. Karin Lachmi and entrepreneur Daniel Levitt.[2][4]
Dr. Lachmi, a computational biology background, cofounded Bioz to address the problem that researchers lacked an aggregated, searchable source of what products and protocols were actually used in published experiments; the company grew from that academic insight into a commercial AI platform that ingests and structures scientific papers.[2][4]
Early traction included acceptance into the Stanford‑StartX accelerator, rapid user adoption (company claims over one million researcher users across many institutions), and recognition for its founders and platform in regional awards and press.[2][4]
Core Differentiators
Role in the Broader Tech Landscape
Bioz rides several converging trends: the application of AI/NLP to vertical, specialized knowledge domains; the push for reproducibility and transparency in life‑science research; and digital transformation of scientific supply chains where buyers demand data‑driven validation of products.[1][4]
Timing matters because the growth of open literature, preprints, and increased emphasis on reproducibility create a rich data environment for text‑mining, and biopharma’s need to accelerate R&D budgets favors tools that reduce failed experiments and procurement friction.[1][4]
Market forces in Bioz’s favor include expanding volumes of published experimental data, digitally native procurement channels for lab supplies, and vendors’ willingness to pay for third‑party validation to differentiate products online.[3][1]
By making literature‑based evidence accessible at the point of product choice, Bioz influences procurement behavior, vendor marketing strategies, and researcher workflows—contributing to higher standards for documented experimental validation across the ecosystem.[4][3]
Quick Take & Future Outlook
What’s next: continued expansion of its literature coverage, deeper extraction of protocol and condition metadata (to move beyond product citation to actionable experimental parameters), and broader integrations with vendor e‑commerce platforms and lab informatics systems.[1][3]
Trends to watch that will shape Bioz’s trajectory include advances in scientific NLP (better entity linking and protocol understanding), growth in preprint and open‑access content (more raw signal), and increasing demand from biopharma for tools that reduce experimental failure and speed candidate selection.[1][4]
Potential challenges include maintaining extraction accuracy as literature formats diversify, competitive pressure from larger data/AI entrants into scientific search, and the need to prove measurable ROI to enterprise customers to sustain monetization.[1][4]
Overall, Bioz sits at the intersection of AI and life‑science workflows—its evidence‑based approach addresses a clear researcher pain point, and its influence will likely grow as the scientific R&D stack becomes more data driven and procurement more transparent.[2][4]
Bioz has raised $44.0M across 3 funding rounds. Most recently, it raised $40.0M Series A in March 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2021 | $40.0M Series A | BoxOne Ventures, Harmonix Fund, Pioneer Fund, Mathieu Guerville | |
| Jan 1, 2019 | $2.0M Series A | Storm Ventures, Wildcat Ventures | |
| Jul 1, 2016 | $2.0M Seed | Storm Ventures, Thomvest Ventures, Wildcat Ventures |
